Breaking Down the Product Hierarchy: Sensors, Strips, and Software in the Europe Blood Glucose Monitoring Market Segment
To understand the internal mechanics of the industry, one must analyze the specific Europe Blood Glucose Monitoring Market segment performance, particularly the division between hardware and consumables. While the initial sale of a reader or a smart-watch-integrated app might grab headlines, the recurring revenue from sensors and test strips remains the financial backbone of most companies. The "razor and blade" business model is highly prevalent here; companies often provide the monitoring device at a low cost to lock the user into a long-term subscription for the disposable sensors. However, as CGM technology matures, the "software-as-a-service" (SaaS) model is also gaining ground. Patients and clinics are increasingly paying for advanced data analysis tools, personalized coaching, and integration services that turn raw glucose readings into actionable therapy plans.
Ref - https://www.marketresearchfuture.com/reports/emea-blood-glucose-monitoring-market-607
The "Self-Monitoring Blood Glucose" (SMBG) segment, which consists of traditional meters and strips, still holds a significant portion of the market, particularly among patients with Type 2 diabetes who do not require intensive insulin management. However, this segment is facing increasing pressure as low-cost, intermittently-scanned CGMs become more affordable. Many industry experts predict that the traditional meter will eventually be relegated to a backup role, used only for calibration or in emergency situations. The hospital segment is also seeing a shift, as clinical-grade continuous monitors are being introduced into intensive care units and surgical wards to manage "stress hyperglycemia" in non-diabetic patients. This diversification of use cases across different medical segments is ensuring a broad and resilient market landscape.
To understand the internal mechanics of the industry, one must analyze the specific Europe Blood Glucose Monitoring Market segment performance, particularly the division between hardware and consumables. While the initial sale of a reader or a smart-watch-integrated app might grab headlines, the recurring revenue from sensors and test strips remains the financial backbone of most companies. The "razor and blade" business model is highly prevalent here; companies often provide the monitoring device at a low cost to lock the user into a long-term subscription for the disposable sensors. However, as CGM technology matures, the "software-as-a-service" (SaaS) model is also gaining ground. Patients and clinics are increasingly paying for advanced data analysis tools, personalized coaching, and integration services that turn raw glucose readings into actionable therapy plans.
Ref - https://www.marketresearchfuture.com/reports/emea-blood-glucose-monitoring-market-607
The "Self-Monitoring Blood Glucose" (SMBG) segment, which consists of traditional meters and strips, still holds a significant portion of the market, particularly among patients with Type 2 diabetes who do not require intensive insulin management. However, this segment is facing increasing pressure as low-cost, intermittently-scanned CGMs become more affordable. Many industry experts predict that the traditional meter will eventually be relegated to a backup role, used only for calibration or in emergency situations. The hospital segment is also seeing a shift, as clinical-grade continuous monitors are being introduced into intensive care units and surgical wards to manage "stress hyperglycemia" in non-diabetic patients. This diversification of use cases across different medical segments is ensuring a broad and resilient market landscape.
Breaking Down the Product Hierarchy: Sensors, Strips, and Software in the Europe Blood Glucose Monitoring Market Segment
To understand the internal mechanics of the industry, one must analyze the specific Europe Blood Glucose Monitoring Market segment performance, particularly the division between hardware and consumables. While the initial sale of a reader or a smart-watch-integrated app might grab headlines, the recurring revenue from sensors and test strips remains the financial backbone of most companies. The "razor and blade" business model is highly prevalent here; companies often provide the monitoring device at a low cost to lock the user into a long-term subscription for the disposable sensors. However, as CGM technology matures, the "software-as-a-service" (SaaS) model is also gaining ground. Patients and clinics are increasingly paying for advanced data analysis tools, personalized coaching, and integration services that turn raw glucose readings into actionable therapy plans.
Ref - https://www.marketresearchfuture.com/reports/emea-blood-glucose-monitoring-market-607
The "Self-Monitoring Blood Glucose" (SMBG) segment, which consists of traditional meters and strips, still holds a significant portion of the market, particularly among patients with Type 2 diabetes who do not require intensive insulin management. However, this segment is facing increasing pressure as low-cost, intermittently-scanned CGMs become more affordable. Many industry experts predict that the traditional meter will eventually be relegated to a backup role, used only for calibration or in emergency situations. The hospital segment is also seeing a shift, as clinical-grade continuous monitors are being introduced into intensive care units and surgical wards to manage "stress hyperglycemia" in non-diabetic patients. This diversification of use cases across different medical segments is ensuring a broad and resilient market landscape.
0 Reacties
·0 aandelen
·162 Views
·0 voorbeeld